Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Scivision Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$251.4 Mil. Scivision Biotech's average Accounts Receivable for the
three
months ended in Dec. 2025 was NT$184.0 Mil.
Hence, Scivision Biotech's Receivables Turnover for the
three
months ended in Dec. 2025 was 1.37.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Scivision Biotech Receivables Turnover Related Terms
Scivision Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Scivision Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1786 vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Scivision Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech (TPE:1786) has a Receivables Turnover of 1.37 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scivision Biotech and its competitors. According to the industry distribution chart, Scivision Biotech ranks #422 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 52%.
Is Scivision Biotech's Receivables Turnover too high?
Scivision Biotech's current Receivables Turnover is 1.37. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Scivision Biotech's value of 1.37 is 75.1% below this industry median. Based on the distribution chart, Scivision Biotech ranks #422 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Scivision Biotech has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #422 out of 811 companies for Receivables Turnover. This places Scivision Biotech in the lower half of its industry. The industry median Receivables Turnover is 5.51. Scivision Biotech's value of 1.37 is 75.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current Receivables Turnover of 1.37 is 75.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scivision Biotech and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current Receivables Turnover is 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$116.19, compared to a current price of NT$48.50 — trading 58.3% below its estimated fair value. The current Receivables Turnover is 1.37 and 75.1% below the Medical Devices & Instruments industry median of 5.51. Scivision Biotech's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Receivables Turnover is 1.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$48.50 is trading 58.3% below its estimated GF Value™ of NT$116.19.
GuruFocus considers Scivision Biotech to be Possible Value Trap.
Key valuation signals for TPE:1786:
Receivables Turnover: 1.37
GF Value™: NT$116.19 vs. price of NT$48.50 (58.3% below fair value)
Industry Position: 75.1% below the Medical Devices & Instruments median (#422 of 811)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
75GF Score
Get the complete analysis for TPE:1786
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
